吸入性糖皮质激素预防早产儿慢性肺疾病有效性和安全性的meta分析  

Meta-analysis of the efficacy and safety of inhaled corticosteroids for preventing chronic lung disease in preterm infants

作　　者：王小玲 李雄 雷小平 康兰 王胜会 董文斌 

机构地区：[1]西南医科大学附属医院新生儿科,四川泸州646000

出　　处：《临床儿科杂志》2017年第6期467-474,共8页Journal of Clinical Pediatrics

摘　　要：目的系统评价吸入性糖皮质激素预防早产儿慢性肺疾病(CLD)的有效性和安全性。方法计算机检索Pub Med、EMBASE、CENTRAL、the ISI Web of Knowledge Databases、CBM、CNKI和VIP、Wan Fang Data,检索时限均为建库至2016年10月,搜集所有研究吸入性糖皮质激素防治早产儿CLD的疗效和安全性的随机对照试验(RCT),并进行RCT的筛选、资料提取和质量评价,应用Rev Man 5.3软件进行meta分析。结果共纳入12篇RCT,2 051例早产儿。与对照组比较,28天组吸入糖皮质激素组,以及吸入布地奈德亚组、倍氯米松亚组和氟替卡松亚组,CLD发生率的差异无统计学意义(P均>0.05)。与对照组比较,校正胎龄36周组吸入糖皮质激素组(RR=0.70,95%CI:0.61~0.80)、雾化吸入亚组(RR=0.74,95%CI:0.63~0.87)、气管内给药亚组(RR=0.57,95%CI:0.43~0.76)以及布地奈德亚组(RR=0.67;95%CI:0.57~0.78)和氟替卡松亚组(RR=0.58,95%CI:0.36~0.94),CLD发生率的差异有统计学意义(P均<0.05);而倍氯米松组CLD发生率与对照组差异无统计学意义(P=0.90);总的病死率差异无统计学意义(P=0.55);雾化吸入亚组和气管内给药亚组以及布地奈德亚组、倍氯米松亚组和氟替卡松亚组病死率与对照组比较差异无统计学意义(P均>0.05)。结论预防性使用吸入性糖皮质激素能有效降低早产儿CLD的发病率,但对病死率无影响,与给药方式和给药类型无显著相关性。同时推荐以校正胎龄36周为结局指标观察点,但相关研究数量有限,且缺乏长期随访结果,因此吸入性糖皮质激素的作用及远期并发症,仍需大量的临床研究来评估,建议临床谨慎使用。ObjectiveTo evaluate the effcacy and safety of inhaled corticosteroids for preventing chronic lung disease （CLD） in preterm infants. MethodsPubMed, EMBASE, CENTRAL, the ISI Web of Knowledge databases, CBM, CNKI, VIP and Wanfang Data were searched for the period up to Oct. 2016. All randomized controlled trials （RCTs） about inhaled corticosteroids for preventing CLD in preterm infants were collected. The RCTs had been screened, data were extracted and assessed. The mata-analysis was performed by RevMan 5.3 software. ResultA total of 12 RCTs were included （a total of 2051 preterm neonates）. Compared with control group, in 28 day old group, the incidence of CLD was not significantly different between experimental and control groups （RR=0.87, 95%CI：0.74-1.03, P=0.11） and （RR=1.19, 95%CI：0.59-2.43, P=0.63） and no signifcant difference among subgroups budesonide （α）, beclomethasone （β）, futicasone （γ） （RR=0.89, 95%CI：0.69-1.14, P=0.35）, （RR=0.86, 95%CI：0.69-1.08, P=0.19） and （RR=0.91, 95%CI：0.60-1.38, P=0.19）. In 36 wk postmenstrual age group,the incidence of CLD was decreased in experimental group and in subgroups inhalation （A）, Intratracheal administration （B）, α, γ （RR=0.70, 95%CI： 0.61-0.80, P〈0.00001）, （RR=0.74, 95%CI： 0.63-0.87, P=0.0003）, （RR=0.57, 95%CI： 0.43-0.76, P=0.0002）, （RR=0.67, 95%CI： 0.57-0.78, P〈0.00001） and （RR=0.58, 95%CI： 0.36-0.94, P=0.03）; but it is not significantly different in subgroup β （RR=0.98, 95%CI： 0.69-1.39, P=0.90）; There was no difference in the motality in experimental and subgroups A ,B, α, β , γ （RR=1.07, 95%CI：0.86-1.33, P=0.55）, （RR=1.24, 95%CI： 0.97-1.59, P=0.09）, （RR=0.67, 95%CI： 0.43-1.03, P=0.07）, （RR=1.04, 95%CI： 0.81-1.33, P=0.78）, （RR=1.47, 95%CI： 0.79-2.74, P=0.22） and （RR=0.91, 95%CI： 0.47-1.74, P=0.77）. No clinically signifcant adverse effects were observed during the study. ConclusionsThis updated review indicated t

关 键 词：吸入性糖皮质激素 慢性肺疾病 早产儿 

分 类 号：R722.6[医药卫生—儿科]